Human papillomavirus molecular biology and disease association

Reviews in Medical Virology

Volumn 25, Issue S1, 2015, Pages 2-23

  Doorbar, John ^a   Egawa, Nagayasu ^a   Griffin, Heather ^a   Kranjec, Christian ^a   Murakami, Isao ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANUS CANCER; CELL SURFACE; CLINICAL FEATURE; CONDYLOMA ACUMINATUM; DISEASE ASSOCIATION; EPIDERMOID CYST; EPITHELIUM; EPITHELIUM BASAL CELL; FILIFORM WART; FLAT WART; GENE AMPLIFICATION; GENETIC ORGANIZATION; GENOME ANALYSIS; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; LIFE CYCLE; META ANALYSIS (TOPIC); MICROBIAL DIVERSITY; MOLECULAR BIOLOGY; NONHUMAN; PAPILLOMA VIRUS; PDZ DOMAIN; PENIS CANCER; PIGMENTED WART; REVIEW; SKIN CANCER; UTERINE CERVIX CARCINOMA IN SITU; VAGINA CANCER; VERRUCA PLANTARIS; VERRUCA VULGARIS; VIRAL GENETICS; VIRAL SKIN DISEASE; VIRAL TROPISM; VIRUS ASSEMBLY; VIRUS ENTRY; VIRUS MORPHOLOGY; VIRUS RELEASE; WART VIRUS; ANIMAL; GENETICS; METABOLISM; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; VIROLOGY; VIRUS GENOME;

ONCOPROTEIN;

ANIMALS; GENOME, VIRAL; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 84924029213     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1822     Document Type: Review

References (250)

1. Bravo IG, de Sanjose S, Gottschling M. The clinical importance of understanding the evolution of papillomaviruses. Trends in Microbiology 2010; 18(10): 432-438.
2. Antonsson A, McMillan NA. Papillomavirus in healthy skin of Australian animals. Journal of General Virology 2006; 87(Pt 11): 3195-3200.
3. Antonsson A, et al. General acquisition of human papillomavirus infections of skin occurs in early infancy. Journal of Clinical Microbiology 2003; 41(6): 2509-2514.
4. Antonsson A, et al. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. Journal of Virology 2000; 74(24): 11636-11641.
5. Griffiths P. Time to consider the concept of a commensal virus? Reviews in Medical Virology 1999; 9(2): 73-74.
6. Doorbar J, et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30(Suppl 5): F55-F70.
7. zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009; 384(2): 260-265.
8. Goon P, et al. Recurrent respiratory papillomatosis: an overview of current thinking and treatment. European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies 2008; 265(2): 147-151.
9. Gerein V, et al. Incidence, age at onset, and potential reasons of malignant transformation in recurrent respiratory papillomatosis patients: 20years experience. Otolaryngology - Head and Neck Surgery, 2005; 132(3): 392-394.
10. Bernard HU, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401(1): 70-79.
11. de Villiers EM. Cross-roads in the classification of papillomaviruses. Virology 2013; 445(1-2): 2-10.
12. Steinberg BM, et al. Tissue site-specific enhancer function of the upstream regulatory region of human papillomavirus type 11 in cultured keratinocytes. Journal of Virology 1989; 63(2): 957-960.
13. Syrjanen S. Human papillomavirus infections and oral tumors. Medical Microbiology and Immunology (Berl) 2003; 192(3): 123-128.
14. Mistry N, Wibom C, Evander M. Cutaneous and mucosal human papillomaviruses differ in net surface charge, potential impact on tropism. Virology Journal 2008; 5: 118.
15. Giroglou T, et al. Human papillomavirus infection requires cell surface heparan sulfate. Journal of Virology 2001; 75(3): 1565-1570.
16. Kines RC, et al. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proceedings of the National Academy of Sciences of the United States of America 2009; 106(48): 20458-20463.
17. Selinka HC, et al. Further evidence that papillomavirus capsids exist in two distinct conformations. Journal of Virology 2003; 77(24): 12961-12967.
18. Joyce JG, et al. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. Journal of Biological Chemistry 1999; 274(9): 5810-5822.
19. Combita AL, et al. Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate. FEMS Microbiology Letters 2001; 204(1): 183-188.
20. Shafti-Keramat S, et al. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. Journal of Virology 2003; 77(24): 13125-13135.
21. Johnson KM, et al. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. Journal of Virology 2009; 83(5): 2067-2074.
22. Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecologic Oncology 2010; 118(Suppl 1): S12-S17.
23. Egawa K, et al. Varied clinical morphology of HPV-1-induced warts, depending on anatomical factors. British Journal of Dermatology 1993; 128: 271-276.
24. Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Frontiers in Bioscience 2006; 11: 2286-2302.
25. Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nature Reviews. Microbiology 2012; 10(10): 681-692.
26. Chen XS, et al. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Molecular Cell 2000; 5(3): 557-567.
27. Chen XS, et al. Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. Journal of Molecular Biology 2001; 307(1): 173-182.
28. Modis Y, Trus BL, Harrison SC. Atomic model of the papillomavirus capsid. EMBO Journal 2002; 21(18): 4754-4762.
29. Wolf M, et al. Subunit interactions in bovine papillomavirus. Proceedings of the National Academy of Sciences of the United States of America 2010; 107(14): 6298-6303.
30. Rubio I, et al. The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies. Virology 2011; 409(2): 348-359.
31. Liu WJ, et al. Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions. Virology 1997; 227(2): 474-483.
32. Wang JW, Roden RB. L2, the minor capsid protein of papillomavirus. Virology 2013; 445(1-2): 175-186.
33. Dimaio D, Petti LM. The E5 proteins. Virology 2013; 445(1-2): 99-114.
34. Doorbar J. The E4 protein; structure, function and patterns of expression. Virology 2013; 445(1-2): 80-98.
35. Nobre RJ, et al. E7 oncoprotein of novel human papillomavirus type 108 lacking the E6 gene induces dysplasia in organotypic keratinocyte cultures. Journal of Virology 2009; 83(7): 2907-2916.
36. Stanley M. Immune responses to human papillomavirus. Vaccine 2006; 24(Suppl 1): S16-S22.
37. Bruni L, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. The Journal of Infectious Diseases 2010; 202(12): 1789-1799.
38. Guan P, et al. Human papillomavirus types in 115, 789 HPV-positive women: a meta-analysis from cervical infection to cancer. International Journal of Cancer Journal international du cancer 2012; 131(10): 2349-2359.
39. Kreimer AR, et al. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sexually Transmitted Diseases 2010; 37(6): 386-391.
40. Bouvard V, et al. A review of human carcinogens-Part B: biological agents. The Lancet Oncology 2009; 10(4): 321-322.
41. Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines-immune responses. Vaccine 2012; 30(Suppl 5): F83-F87.
42. Woodhall S, et al. Estimation of the impact of genital warts on health-related quality of life. Sexually Transmitted Infections 2008; 84(3): 161-166.
43. Majewski S, Jablonska S. Human papillomavirus-associated tumors of the skin and mucosa. Journal of the American Academy of Dermatology 1997; 36(5 Pt 1): 659-685; quiz 686-8.
44. Chuang TY. Condylomata acuminata (genital warts): an epidemiologic view. Journal of the American Academy of Dermatology 1987; 16(2 Pt 1): 376-384.
45. Clifford GM, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366(9490): 991-998.
46. Petry KU, et al. Prevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84 -results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infectious Diseases 2012; 12: 367.
47. McKee PH, et al. Carcinoma cuniculatum: a cast metastasizing to skin and lymph nodes. Clinical and Experimental Dermatology 1981; 6(6): 613-618.
48. Vera-Iglesias E, et al. Focal epithelial hyperplasia. Actas Dermo-Sifiliográficas 2007; 98(9): 621-623.
49. Bedoui S, et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nature Immunology 2009; 10(5): 488-495.
50. Jenkins D. Histopathology and cytopathology of cervical cancer. Disease Markers 2007; 23(4): 199-212.
51. Solomon D, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA, the Journal of the American Medical Association 2002; 287(16): 2114-2119.
52. Munoz N, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine 2003; 348(6): 518-527.
53. Hording U, et al. Human papillomaviruses and multifocal genital neoplasia. International Journal of Gynecological Pathology 1996; 15(3): 230-234.
54. Toki T, et al. Probable nonpapillomavirus etiology of squamous cell carcinoma of the vulva in older women: a clinicopathologic study using in situ hybridization and polymerase chain reaction. International Journal of Gynecological Pathology 1991; 10(2): 107-125.
55. Rubin MA, et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. American Journal of Pathology 2001; 159(4): 1211-1218.
56. De Vuyst H, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. International Journal of Cancer 2009; 124(7): 1626-1636.
57. Mehanna H, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head and Neck 2013; 35(5): 747-755.
58. Herrero R, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. Journal of the National Cancer Institute 2003; 95(23): 1772-1783.
59. de Koning MN, et al. Evaluation of a novel broad-spectrum PCR-multiplex genotyping assay for identification of cutaneous wart-associated human papillomavirus types. Journal of Clinical Microbiology 2010; 48(5): 1706-1711.
60. Harwood CA, et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. Journal of Medical Virology 2000; 61(3): 289-297.
61. Sterling JC, Handfield-Jones S, Hudson PM. Guidelines for the management of cutaneous warts. The British Journal of Dermatology 2001; 144(1): 4-11.
62. Barrera-Oro JG, Smith KO, Melnick JL. Quantitation of papova virus particles in human warts. Journal of the National Cancer Institute 1962; 29: 583-595.
63. Cubie HA. Diseases associated with human papillomavirus infection. Virology 2013; 445(1-2): 21-34.
64. Jablonska S, et al. Cutaneous warts. Clinics in Dermatology 1997; 15(3): 309-319.
65. Beutner KR, Becker TM, Stone KM. Epidemiology of human papillomavirus infections. Dermatologic Clinics 1991; 9(2): 211-218.
66. van Haalen FM, et al. Warts in primary schoolchildren: prevalence and relation with environmental factors. British Journal of Dermatology 2009; 161(1): 148-152.
67. Rubben A, Krones R, Schwetschenau B, et al. Common warts from immunocompetent patients show the same distribution of human papilloma-viruses types as common warts from immunocompromised patients. British Journal of Dermatology 1993; 128: 264-270.
68. Rubben A, Kalka K, Spelten B, et al. Clinical features and age distribuition of patients with HPV 2/27/57- induced common warts. Archives of Dermatological Research 1997; 289: 337-340.
69. Hagiwara K, Uezato H, Arakaki H, et al. A genotype distribuition of human papillomaviruses detected by polymerase chain reaction and direct sequencing analysis in a large sample of common warts in Japan. Journal of Medical Virology 2005; 77: 107-112.
70. Keefe M, et al. Cutaneous warts in butchers. British Journal of Dermatology 1994; 130(1): 9-14.
71. Grayson W. Infectious diseases of the skin. In Mckee's Skin Pathology with Clinical Correlations, Calonje BTE, Lazar A, Mckee P (eds). Elsevier: Toronto, 2012; 760-895.
72. McKee PH, et al. Carcinoma (epithelioma) cuniculatum: a clinico-pathological study of nineteen cases and review of the literature. Histopathology 1981; 5(4): 425-436.
73. Sterling JC. Viral infections. In Textbook of Dematology, Murns BST, Cox N, Griffiyths C(eds). Blackwell Science: Oxford, 2004; 37-60.
74. Egawa K, et al. Pigmented viral warts: a clinical and histopathological study including human papillomavirus typing. British Journal of Dermatology 1998; 138(3): 381-389.
75. Egawa K, et al. Multiple plantar epidermoid cysts harboring carcinoembryonic antigen and human papillomavirus DNA sequences. Journal of the American Academy of Dermatology 1994; 30(3): 494-496.
76. Egawa K, et al. Human papillomavirus 57 identified in a plantar epidermoid cyst. British Journal of Dermatology 1998; 138(3): 510-514.
77. Meyer LM, Tyring SK, Little WP. Verrucous cyst. Archives of Dermatology 1991; 127(12): 1810-1812.
78. Elston DM, Parker LU, Tuthill RJ. Epidermoid cyst of the scalp containing human papillomavirus. Journal of Cutaneous Pathology 1993; 20(2): 184-186.
79. Egawa K, Egawa N, Honda Y. Human papillomavirus-associated plantar epidermoid cyst related to epidermoid metaplasia of the eccrine duct epithelium: a combined histological, immunohistochemical, DNA-DNA in situ hybridization and three-dimensional reconstruction analysis. British Journal of Dermatology 2005; 152(5): 961-967.
80. Zheng S, et al. Human papillomaviruses of the mucosal type are present in some cases of extragenital Bowen's disease. British Journal of Dermatology 2005; 152(6): 1243-1247.
81. Forslund O, et al. Cutaneous human papillomaviruses found in sun-exposed skin: beta-papillomavirus species 2 predominates in squamous cell carcinoma. Journal of Infectious Diseases 2007; 196(6): 876-883.
82. Alam M, Caldwell JB, Eliezri YD. Human papillomavirus-associated digital squamous cell carcinoma: literature review and report of 21 new cases. Journal of the American Academy of Dermatology 2003; 48(3): 385-393.
83. Bouwes Bavinck JN, et al. Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Research 2010; 70(23): 9777-9786.
84. Gariglio P, et al. The role of retinoid deficiency and estrogens as cofactors in cervical cancer. Archives of Medical Research 2009; 40(6): 449-465.
85. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clinical Science (London) 2006; 110(5): 525-541.
86. Melsheimer P, et al. DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Clinical Cancer Research 2004; 10(9): 3059-3063.
87. Egawa K. Do human papillomaviruses target epidermal stem cells? Dermatology 2003; 207(3): 251-254.
88. Schmitt A, et al. The primary target cells of the high-risk cottontail rabbit papillomavirus colocalize with hair follicle stem cells. Journal of Virology 1996; 70(3): 1912-1922.
89. Schelhaas M, et al. Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS Pathogens 2012; 8(4): e1002657.
90. Smith JL, et al. Caveolin-1-dependent infectious entry of human papillomavirus type 31 in human keratinocytes proceeds to the endosomal pathway for pH-dependent uncoating. Journal of Virology 2008; 82(19): 9505-9512.
91. Bousarghin L, et al. Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells. Journal of Virology 2003; 77(6): 3846-3850.
92. Day PM, Lowy DR, Schiller JT. Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 2003; 307(1): 1-11.
93. Hindmarsh PL, Laimins LA. Mechanisms regulating expression of the HPV 31L1 and L2 capsid proteins and pseudovirion entry. Virology Journal 2007; 4: 19.
94. Pyeon D, et al. Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathogen 2009; 5(2): e1000318.
95. Grayson W, et al. Detection of human papillomavirus in large cell neuroendocrine carcinoma of the uterine cervix: a study of 12 cases. Journal of Clinical Pathology 2002; 55(2): 108-114.
96. Gravitt PE, et al. Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2001; 10(2): 95-100.
97. Bouvard V, et al. Carcinogenicity of malaria and of some polyomaviruses. The Lancet Oncology 2012; 13(4): 339-340.
98. Herfs M, et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proceedings of the National Academy of Sciences of the United States of America 2012; 109(26): 10516-10521.
99. Parish JL, et al. ChlR1 is required for loading papillomavirus E2 onto mitotic chromosomes and viral genome maintenance. Molecular Cell 2006; 24(6): 867-876.
100. Maglennon GA, McIntosh P, Doorbar J, Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology 2011; 414(2): 153-163.
101. Kim K, Lambert PF. E1 protein of bovine papillomavirus 1 is not required for the maintenance of viral plasmid DNA replication. Virology 2002; 293(1): 10-14.
102. Angeletti PC, et al. Stable replication of papillomavirus genomes in Saccharomyces cerevisiae. Journal of Virology 2002; 76(7): 3350-3358.
103. Egawa N, et al. The E1 protein of human papillomavirus type 16 is dispensable for maintenance replication of the viral genome. Journal of Virology 2012; 86(6): 3276-3283.
104. Blakaj DM, et al. Evolutionary and biophysical relationships among the papillomavirus E2 proteins. Frontiers in Bioscience (Landmark Ed) 2009; 14: 900-917.
105. McBride AA. The papillomavirus E2 proteins. Virology 2013; 445(1-2): 57-79.
106. McBride AA, Oliveira JG, McPhillips MG. Partitioning viral genomes in mitosis: same idea, different targets. Cell Cycle 2006; 5(14): 1499-1502.
107. Van Tine BA, et al. Human papillomavirus (HPV) origin-binding protein associates with mitotic spindles to enable viral DNA partitioning. Proceedings of the National Academy of Sciences of the United States of America 2004; 101(12): 4030-4035.
108. Dao LD, et al. Dynamic localization of the human papillomavirus type 11 origin binding protein E2 through mitosis while in association with the spindle apparatus. Journal of Virology 2006; 80(10): 4792-4800.
109. Parish JL, et al. The DNA helicase ChlR1 is required for sister chromatid cohesion in mammalian cells. Journal of Cell Science 2006; 119(Pt 23): 4857-4865.
110. Wang X, et al. Recruitment of Brd4 to the human papillomavirus type 16 DNA replication complex is essential for replication of viral DNA. Journal of Virology 2013; 87(7): 3871-3884.
111. Valencia C, et al. Human papillomavirus E6/E7 oncogenes promote mouse ear regeneration by increasing the rate of wound re-epithelization and epidermal growth. The Journal of Investigative Dermatology 2008; 128(12): 2894-2903.
112. Rosenberger S, et al. Alternative splicing of human papillomavirus type-16 E6/E6* early mRNA is coupled to EGF signaling via Erk1/2 activation. Proceedings of the National Academy of Sciences of the United States of America 2010; 107(15): 7006-7011.
113. Klingelhutz AJ, Roman A. Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses. Virology 2012; 424(2): 77-98.
114. Isaacson Wechsler E, et al. Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression. Journal of Virology 2012; 86(11): 6358-6364.
115. Barrow-Laing L, Chen W, Roman A. Low- and high-risk human papillomavirus E7 proteins regulate p130 differently. Virology 2010; 400(2): 233-239.
116. Roman A. The human papillomavirus E7 protein shines a spotlight on the pRB family member, p130. Cell Cycle 2006; 5(6): 567-568.
117. Felsani A, Mileo AM, Paggi MG. Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene 2006; 25(38): 5277-5285.
118. Phelps WC, et al. Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. Journal of Virology 1992; 66(4): 2418-2427.
119. Watanabe S, Yoshiike K. Transformation of rat 3Y1 cells by human papillomavirus type-18 DNA. International Journal of Cancer 1988; 41(6): 896-900.
120. Brehm A, et al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO Journal 1999; 18(9): 2449-2458.
121. Nguyen DX, Westbrook TF, McCance DJ. Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest. Journal of Virology 2002; 76(2): 619-632.
122. McLaughlin-Drubin ME, Crum CP, Munger K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proceedings of the National Academy of Sciences of the United States of America 2011; 108(5): 2130-2135.
123. Holland D, et al. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. Cancer Research 2008; 68(23): 9964-9972.
124. La Celle PT, Polakowska RR. Human homeobox HOXA7 regulates keratinocyte transglutaminase type 1 and inhibits differentiation. Journal of Biological Chemistry 2001; 276(35): 32844-32853.
125. Morasso MI, Markova NG, Sargent TD. Regulation of epidermal differentiation by a Distal-less homeodomain gene. Journal of Cell Biology 1996; 135(6 Pt 2): 1879-1887.
126. Javier RT. Cell polarity proteins: common targets for tumorigenic human viruses. Oncogene 2008; 27(55): 7031-7046.
127. Culp TD, et al. Papillomavirus particles assembled in 293TT cells are infectious in vivo. Journal of Virology 2006; 80(22): 11381-11384.
128. Kranjec C, Banks L. A systematic analysis of human papillomavirus (HPV) E6 PDZ substrates identifies MAGI-1 as a major target of HPV type 16 (HPV-16) and HPV-18 whose loss accompanies disruption of tight junctions. Journal of Virology 2011; 85(4): 1757-1764.
129. Massimi P, et al. Regulation of the hDlg/hScrib/Hugl-1 tumour suppressor complex. Experimental Cell Research 2008; 314(18): 3306-3317.
130. Pim D, et al. Human papillomaviruses and the specificity of PDZ domain targeting. FEBS Journal 2012; 279(19): 3530-3537.
131. Thomas M, et al. Analysis of specificity determinants in the interactions of different HPV E6 proteins with their PDZ domain-containing substrates. Virology 2008; 376(2): 371-378.
132. Elsum I, et al. The Scribble-Dlg-Lgl polarity module in development and cancer: from flies to man. Essays in Biochemistry 2012; 53: 141-168.
133. Nicolaides L, et al. Stabilization of HPV16 E6 protein by PDZ proteins, and potential implications for genome maintenance. Virology 2011; 414(2): 137-145.
134. Massimi P, et al. Phosphorylation of the discs large tumour suppressor protein controls its membrane localisation and enhances its susceptibility to HPV E6-induced degradation. Oncogene 2006; 25(31): 4276-4285.
135. Lee C, Laimins LA. Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31. Journal of Virology 2004; 78(22): 12366-12377.
136. Delury CP, et al. The role of protein kinase A regulation of the E6 PDZ-binding domain during the differentiation-dependent life cycle of human papillomavirus type 18. Journal of Virology 2013; 87(17): 9463-9472.
137. Russo AJ, et al. E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Research 2006; 66(14): 7253-7260.
138. Malanchi I, et al. Human papillomavirus type 16 E6 promotes retinoblastoma protein phosphorylation and cell cycle progression. Journal of Virology 2004; 78(24): 13769-13778.
139. Kuhne C, et al. Differential regulation of human papillomavirus E6 by protein kinase A: conditional degradation of human discs large protein by oncogenic E6. Oncogene 2000; 19(51): 5884-5891.
140. Boon SS, Banks L. High-risk human papillomavirus E6 oncoproteins interact with 14-3-3zeta in a PDZ binding motif-dependent manner. Journal of Virology 2013; 87(3): 1586-1595.
141. Galloway DA, et al. Regulation of telomerase by human papillomaviruses. Cold Spring Harbor Symposia on Quantitative Biology 2005; 70: 209-215.
142. Gewin L, Galloway DA. E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. Journal of Virology 2001; 75(15): 7198-7201.
143. Klingelhutz AJ, Foster SA, McDougall SA. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996; 380: 79-82.
144. Fu L, et al. Degradation of p53 by human Alphapapillomavirus E6 proteins shows a stronger correlation with phylogeny than oncogenicity. PLoS One 2010; 5(9): e12816.
145. Zanier K, et al. Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53. Structure 2012; 20(4): 604-617.
146. Pim D, Banks L. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses. APMIS (Acta Pathologica, Microbiologica et Immunologica Scandinavica) 2010; 118(6-7): 471-493.
147. Tomaic V, Pim D, Banks L. The stability of the human papillomavirus E6 oncoprotein is E6AP dependent. Virology 2009; 393(1): 7-10.
148. White EA, et al. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proceedings of the National Academy of Sciences of the United States of America 2012; 109(5): E260-E267.
149. Nomine Y, et al. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Molecular Cell 2006; 21(5): 665-678.
150. Bodily J, Laimins LA. Persistence of human papillomavirus infection: keys to malignant progression. Trends in Microbiology 2011; 19(1): 33-39.
151. Banerjee NS, et al. Human papillomavirus (HPV) E7 induces prolonged G2 following S phase reentry in differentiated human keratinocytes. Journal of Biological Chemistry 2011; 286(17): 15473-15482.
152. Wang HK, et al. Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes & Development 2009; 23(2): 181-194.
153. Krawczyk E, et al. Koilocytosis: a cooperative interaction between the human papillomavirus E5 and E6 oncoproteins. The American Journal of Pathology 2008; 173(3): 682-688.
154. Krawczyk E, et al. Membrane orientation of the human papillomavirus type 16 E5 oncoprotein. Journal of Virology 2010; 84(4): 1696-1703.
155. Kabsch K, et al. The HPV-16 E5 protein inhibits TRAIL-and FasL-mediated apoptosis in human keratinocyte raft cultures. Intervirology 2004; 47(1): 48-56.
156. Suprynowicz FA, et al. The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification. Journal of Virology 2010; 84(20): 10619-10629.
157. Thomsen P, et al. The HPV16 E5 oncogene inhibits endocytic trafficking. Oncogene 2000; 19(52): 6023-6032.
158. Genther SM, et al. Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. Journal of Virology 2003; 77(5): 2832-2842.
159. Fehrmann F, Klumpp DJ, Laimins LA. Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation. Journal of Virology 2003; 77(5): 2819-2831.
160. Pim D, Collins M, Banks L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene 1992; 7(1): 27-32.
161. Straight S, et al. The E5 oncoprotein of HPV16 transforms fibroblasts and effects the downregulation of the EGF receptor in keratinocytes. Journal of Virology 1993; 69: 4521-4532.
162. Crusius K, Rodriguez I, Alonso A. The human papillomavirus type 16 E5 protein modulates ERK1/2 and p38 MAP kinase activation by an EGFR-independent process in stressed human keratinocytes. Virus Genes 2000; 20(1): 65-69.
163. Crusius K, et al. The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Experimental Cell Research 1998; 241(1): 76-83.
164. Yu JH, et al. Mitogen-activated protein kinases activate the nuclear localization sequence of human papillomavirus type 11 E1 DNA helicase to promote efficient nuclear import. Journal of Virology 2007; 81(10): 5066-5078.
165. Deng W, et al. Cyclin/CDK regulates the nucleocytoplasmic localization of the human papillomavirus E1 DNA helicase. Journal of Virology 2004; 78(24): 13954-13965.
166. Moody CA, et al. Human papillomaviruses activate caspases upon epithelial differentiation to induce viral genome amplification. Proceedings of the National Academy of Sciences of the United States of America 2007; 104(49): 19541-19546.
167. Doorbar J, et al. Characterization of events during the late stages of HPV16 infection in vivo using high-affinity synthetic Fabs to E4. Virology 1997; 238(1): 40-52.
168. McIntosh PB, et al. Structural analysis reveals an amyloid form of the human papillomavirus type 16 E1^E4 protein and provides a molecular basis for its accumulation. Journal of Virology 2008; 82(16): 8196-8203.
169. Doorbar J, et al. Specific interaction between HPV-16 E1^E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature 1991; 352(6338): 824-827.
170. Wang Q, et al. Functional analysis of the human papillomavirus type 16 E1^E4 protein provides a mechanism for in vivo and in vitro keratin filament reorganization. Journal of Virology 2004; 78(2): 821-833.
171. Gulliksen A, et al. Towards a " Sample-In, Answer-Out" Point-of-Care Platform for Nucleic Acid Extraction and Amplification: Using an HPV E6/E7 mRNA Model System. Journal of Oncology 2012; 2012: 905024.
172. Wilson R, Fehrmann F, Laimins LA. Role of the E1^E4 protein in the differentiation-dependent life cycle of human papillomavirus type 31. Journal of Virology 2005; 79(11): 6732-6740.
173. Wilson R, et al. The full-length E1^E4 protein of human papillomavirus type 18 modulates differentiation-dependent viral DNA amplification and late gene expression. Virology 2007; 362(2): 453-460.
174. Nakahara T, et al. Human Papillomavirus Type 16 E1^E4 Contributes to Multiple Facets of the Papillomavirus Life Cycle. Journal of Virology 2005; 79(20): 13150-13165.
175. Peh WL, et al. The viral E4 protein is required for the completion of the cottontail rabbit papillomavirus productive cycle in vivo. Journal of Virology 2004; 78(4): 2142-2151.
176. Ozbun MA, Meyers C. Human papillomavirus type 31b E1 and E2 transcript expression correlates with vegetative viral genome amplification. Virology 1998; 248(2): 218-230.
177. Johansson C, et al. HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation. The EMBO Journal 2012; 31(14): 3212-3227.
178. Doorbar J. The papillomavirus life cycle. Journal of Clinical Virology 2005; 32(Suppl): 7-15.
179. Milligan SG, et al. Analysis of novel human papillomavirus type 16 late mRNAs in differentiated W12 cervical epithelial cells. Virology 2007; 360(1): 172-181.
180. Holmgren SC, et al. The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle. Journal of Virology 2005; 79(7): 3938-3948.
181. Day PM, et al. The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. Journal of Virology 1998; 72(1): 142-150.
182. Buck CB, et al. Maturation of papillomavirus capsids. Journal of Virology 2005; 79(5): 2839-2846.
183. Finnen RL, et al. Interactions between papillomavirus L1 and L2 capsid proteins. Journal of Virology 2003; 77(8): 4818-4826.
184. Brown DR, et al. The human papillomavirus type 11 E1^E4 protein is a transglutaminase 3 substrate and induces abnormalities of the cornified cell envelope. Virology 2006; 345(1): 290-298.
185. Middleton K, et al. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. Journal of Virology 2003; 77(19): 10186-10201.
186. McLaughlin-Drubin ME, Munger K. The human papillomavirus E7 oncoprotein. Virology 2009; 384(2): 335-344.
187. Duensing S, Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Research 2002; 62(23): 7075-7082.
188. Duensing S, Munger K. Human papillomavirus type 16 E7 oncoprotein can induce abnormal centrosome duplication through a mechanism independent of inactivation of retinoblastoma protein family members. Journal of Virology 2003; 77(22): 12331-12335.
189. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. International Journal of Cancer 2004; 109(2): 157-162.
190. Korzeniewski N, et al. Genomic instability and cancer: lessons learned from human papillomaviruses. Cancer Letters 2011; 305(2): 113-122.
191. Duensing A, et al. Centrosome overduplication, chromosomal instability, and human papillomavirus oncoproteins. Environmental and Molecular Mutagenesis 2009; 50(8): 741-747.
192. Oh ST, Longworth MS, Laimins LA. Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. Journal of Virology 2004; 78(5): 2620-2626.
193. Park RB, Androphy EJ. Genetic analysis of high-risk e6 in episomal maintenance of human papillomavirus genomes in primary human keratinocytes. Journal of Virology 2002; 76(22): 11359-11364.
194. Thomas MC, Chiang CM. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Molecular Cell 2005; 17(2): 251-264.
195. Patel D, et al. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO Journal 1999; 18(18): 5061-5072.
196. Pietsch EC, Murphy ME. Low risk HPV-E6 traps p53 in the cytoplasm and induces p53-dependent apoptosis. Cancer Biology and Therapy 2008; 7(12): 1916-1918.
197. Shamanin VA, Sekaric P, Androphy EJ. hAda3 degradation by papillomavirus type 16 E6 correlates with abrogation of the p14ARF-p53 pathway and efficient immortalization of human mammary epithelial cells. Journal of Virology 2008; 82(8): 3912-3920.
198. Sekaric P, et al. hAda3 regulates p14ARF-induced p53 acetylation and senescence. Oncogene 2007; 26(43): 6261-6268.
199. Paavonen J, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369(9580): 2161-2170.
200. Paavonen J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374(9686): 301-314.
201. Szarewski A, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. International Journal of Cancer 2012; 131(1): 106-116.
202. Quint W, et al. One virus, one lesion-individual components of CIN lesions contain a specific HPV type. The Journal of Pathology 2012; 227(1): 62-71.
203. Ding DC, et al. Methylation of the long control region of HPV16 is related to the severity of cervical neoplasia. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2009; 147(2): 215-220.
204. Pater MM, et al. Glucocorticoid-dependent oncogenic transformation by type 16 but not type 11 human papilloma virus DNA. Nature 1988; 335(6193): 832-835.
205. Piccini A, et al. Regulation of human papillomavirus type 16 DNA replication by E2, glucocorticoid hormone and epidermal growth factor. Journal of General Virology 1997; 78(Pt 8): 1963-1970.
206. Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 1996; 93(7): 2930-2935.
207. Vinokurova S, von Knebel Doeberitz M. Differential methylation of the HPV 16 upstream regulatory region during epithelial differentiation and neoplastic transformation. PLoS One 2011; 6(9): e24451.
208. Laurson J, et al. Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. Carcinogenesis 2010; 31(5): 918-926.
209. Hyland PL, et al. Evidence for alteration of EZH2, BMI1, and KDM6A and epigenetic reprogramming in human papillomavirus type 16 E6/E7-expressing keratinocytes. Journal of Virology 2011; 85(21): 10999-11006.
210. Thorland EC, et al. Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene 2003; 22(8): 1225-1237.
211. Yu T, et al. The role of viral integration in the development of cervical cancer. Cancer Genetics and Cytogenetics 2005; 158(1): 27-34.
212. Wentzensen N, et al. Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions. Oncogene 2002; 21(3): 419-426.
213. Jeon S, Allen-Hoffmann BL, Lambert PF. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. Journal of Virology 1995; 69(5): 2989-2997.
214. Jeon S, Lambert PF. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America 1995; 92(5): 1654-1658.
215. Pett MR, et al. Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Research 2004; 64(4): 1359-1368.
216. Hafner N, et al. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 2008; 27(11): 1610-1617.
217. Vinokurova S, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Research 2008; 68(1): 307-313.
218. Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? Journal of Pathology 2007; 212(4): 356-367.
219. Matsukura T, Koi S, Sugase M. Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology 1989; 172(1): 63-72.
220. Fehrmann F, Laimins LA. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 2003; 22(33): 5201-5207.
221. Badaracco G, et al. HPV16 and HPV18 in genital tumors: significantly different levels of viral integration and correlation to tumor invasiveness. Journal of Medical Virology 2002; 67(4): 574-582.
222. Woodman CB, et al. Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet 2003; 361(9351): 40-43.
223. Cullen AP, et al. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasms. Journal of Virology 1991; 65: 606-612.
224. Pirami L, Giache V, Becciolini A. Analysis of HPV16, 18, 31, and 35 DNA in pre-invasive and invasive lesions of the uterine cervix. Journal of Clinical Pathology 1997; 50(7): 600-604.
225. Schiffman M, et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Research 2010; 70(8): 3159-3169.
226. Koshiol JE, et al. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. International Journal of Cancer 2006; 119(7): 1623-1629.
227. de Sanjose S, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. The Lancet Oncology 2010; 11(11): 1048-1056.
228. Nicholls P, et al. Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection. Virology 1999; 265(2): 365-374.
229. Nicholls PK, et al. Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology 2001; 283(1): 31-39.
230. Wilgenburg BJ, et al. Characterization of immune responses during regression of rabbit oral papillomavirus infections. Comparative Medicine 2005; 55(5): 431-439.
231. Monnier-Benoit S, et al. Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix. Gynecologic Oncology 2006; 102(1): 22-31.
232. Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clinical Microbiology Reviews 2012; 25(2): 215-222.
233. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Current Cancer Drug Targets 2007; 7(1): 79-89.
234. Li S, et al. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 1999; 18(42): 5727-5737.
235. Nees M, et al. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. Journal of Virology 2001; 75(9): 4283-4296.
236. Perea SE, Massimi P, Banks L. Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1. International Journal of Molecular Medicine 2000; 5(6): 661-666.
237. Um SJ, et al. Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer Letters 2002; 179(2): 205-212.
238. Caberg JH, et al. Silencing of E7 oncogene restores functional E-cadherin expression in human papillomavirus 16-transformed keratinocytes. Carcinogenesis 2008; 29(7): 1441-1447.
239. Matthews K, et al. Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. Journal of Virology 2003; 77(15): 8378-8385.
240. Zhou F, Chen J, Zhao KN. Human papillomavirus 16-encoded E7 protein inhibits IFN-gamma-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes. Journal of General Virology 2013; 94(Pt 11): 2504-2514.
241. Bottley G, et al. High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene 2008; 27(12): 1794-1799.
242. Georgopoulos NT, Proffitt JL, Blair GE. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene 2000; 19(42): 4930-4935.
243. Ashrafi GH, et al. E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. International Journal of Cancer 2006; 119(9): 2105-2112.
244. Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nature Reviews. Immunology 2008; 8(12): 935-947.
245. Maglennon GA, McIntosh PB, Doorbar J. Immunosuppression facilitates the reactivation of latent papillomavirus infections. Journal of Virology 2013; 88(1): 710-716.
246. de Jong A, et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Research 2004; 64(15): 5449-5455.
247. Welters MJ, et al. Frequent display of human papillomavirus type 16 E6-specific memory t-helper cells in the healthy population as witness of previous viral encounter. Cancer Research 2003; 63(3): 636-641.
248. Ades S, et al. Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. International Journal of Cancer 2008; 122(12): 2820-2826.
249. Sheu BC, et al. Integration of high-risk human papillomavirus DNA correlates with HLA genotype aberration and reduced HLA class I molecule expression in human cervical carcinoma. Clinical Immunology 2005; 115(3): 295-301.
250. Zoodsma M, et al. HLA genes and other candidate genes involved in susceptibility for (pre)neoplastic cervical disease. International Journal of Oncology 2005; 26(3): 769-784.